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Abstract  
 The Albanian vaccination program started in 1960. DTwP vaccine 
was introduced to the immunization schedule since the beginning and was 
produced in the country until the establishment of EPI (Expanded Program 
on Immunization – EPI) in 1993, at the Department of Epidemiology of the 
Institute of Public Health (IPH). From that time the vaccines were procured 
by UNICEF. Until 2003, the reporting of adverse events after vaccination 
was not made through a standard reporting form. The adverse events 
reporting system was implemented in 2003 through the introduction of 
individual reporting forms to the primary health care centers. Although the 
surveillance system was a passive one, the collection of data by IPH was 
made on monthly base and when a signal was detected further investigations 
were undertaken. The pertussis component of Diphtheria, Tetanus, Pertussis 
(DTwP) vaccine is the whole inactivated cell of Bordetella Pertussis. The 
aim of this study is to analyze the rate of adverse events following DTwP 
administration in Albanian children from 2003 to 2015. 
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Introduction 
 Whole cell pertussis vaccines (wP) were firstly produced and world-
wide adopted during the 1940s and were widely accepted despite the local 
and systemic adverse reactions following its administration (Mortimer, 
1994). Since that year diphtheria and tetanus toxoids have been combined 
with pertussis antigens and used as a combination DTwP. In Albania, this 
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vaccine was introduced to the immunization schedule since the beginning of 
vaccination program all over the country in 1960, but untill 2009 it was 
administered as a single inoculation to the Albanian children in a three 
primary dose and one booster dose. In 2009, the Pentavalent vaccine was 
introduced in the immunization schedule and DTwP was co-administered 
with HepB and Hib vaccines in a single formulation (DTP-HepB-Hib). This 
Pentavalent vaccine replaced the traditional DTwP in all the doses. The 
primary doses are administered at 2, 4 and 6 months of age while the booster 
dose is administered at 24 months of age. At the same day, the child receives 
also the OPV(Oral Polio Vaccine). Studies and clinical trials have shown that 
the co-administration of more than one antigen does not increase the rate of 
adverse events of the single one (Bar-On, Goldberg, Hellmann, & Leibovici, 
2012; Decker, Edwards, & Bogaerts, 2008). Administering multiple antigens 
into a single injection reduces pain, local reactions, distress of the child and 
also limits the costs of maintaining the cold chain. 
 There have been a lot of controversies regarding adverse events after 
whole cell pertussis vaccines since it is known as one of the most reactogenic 
vaccines. These vaccines which are suspected to kill the B. pertussis 
organisms might cause frequently minor reactions, infrequently transient 
with moderate severity reactions and rarely serious but self-limited reactions. 
The concerns about safety issues of wP led to the development of acellular 
pertussis (aP) vaccine in the late 1980s which nowadays is used in almost all 
industrialized countries (Institute of Medicine [IOM], 1991). In Albania, wP 
vaccine it is still used, but aP can be obtained through private vaccine 
suppliers. This study was undertaken to compare rates and frequency of local 
and systemic reactions after administration of DTwP-containing vaccines to 
children of 2, 4, 6 and 24 months of age. Most of the events were common 
and there were minor reactions like local reactions but only rare serious 
events. Local reactions included erythema, swelling, pain and tenderness at 
the injection site. Systemic events included generalized urticaria, rash, 
drowsiness, persistent crying, encephalopathy, anaphylaxis and convulsions.   
No deaths were reported. The most used Pentavalent vaccine was 
Quinvaxem (Korea) but also other brands like Bio-Farma (Indonesia), 
GlaxoSmithKline (Belgium) and Indian brands were reported. Taking in 
consideration the WHO information sheets on rates of adverse events of each 
vaccine, it is possible that most of the adverse events reported after 
Pentavalent vaccine administration were related to DTP component (World 
Health Organization [WHO], 2014). The limitations of this study include the 
nature of the AEFI system. Passive surveillance system leads to 
underreporting, over-reporting of minor events in some occasions, errors in 
classification and diagnosis of the events and missing details about some of 
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the events which could make possible a more accurate conclusion about the 
relationship between the vaccine and the adverse event. 
 The aim of this study is: i) to determine whether the adverse events 
after DTwP administration are higher than the rates reported for the DTP 
vaccine in the information sheets published by World Health Organization 
and, ii) to compare the pattern and frequency of these events with those 
reported in other studies of this type. 
 
Material and Methods 
 A retrospective analysis of the adverse events database was 
undertaken using IBM-SPSS ver.21 statistics program. The AEFI database 
was analyzed for adverse events reported following DTwP containing 
vaccines. A total of 275 adverse events were reported after immunization 
with DTP-containing vaccines during a period of 13 years (2003-2015) and 
for a total of 1,825,528 administered doses. Various statistics test were used 
to calculate the difference in group categories, ratios, and frequencies. A p-
value <0.05 was considered statistically significant. 
 
Results 
 Several studies and clinical trials comparing adverse events after 
DTwP or DT vaccine administration have demonstrated that most of the side 
effects associated with DTP administration are related to the whole cell 
pertussis component of the vaccine, although it is largely, but not solely, 
responsible for reactions occurring after administration of the combined 
DTwP vaccine (Gold, Kempe, & Osbourn, 1999 ; Greco et. al., 1996 ; Braun, 
Salive, Chen, & Ellenberg, 2000). The differences are more evident when 
they regard the benign adverse effects such as fever, reactions at the injection 
site and fussiness (Gold et al., 1999 ; Greco et al., 1996). Almost 45 % 
(124/275) of the events were reported in females, 35 % (97/275) in males 
and in 20 % (54/275) of the cases data about gender was missing. The 
overall mean age of vaccinee manifesting an AEFI after DTP administration 
was 6 months (CI 95%: 5,4-7,1). 
 
Reporting Rates after DTwP-containing vaccines throughout years 
 The mean annual reporting rate after DTwP-containing vaccines is 
14.4 cases/100.000 administered doses (p=0.023, CI 95%: 2,25-25,63). The 
distribution of the AEFI rates is not the same throughout years (p=0.045) but 
shows two peak levels. In the Figure1 the first peak level is observed in 2004 
which corresponds to the second year after implementation of AEFI 
reporting system. This is due to increased awareness and trainings of health 
care workers by campaigns undertaken by the Institute of Public Health. The 
second peak is observed during 2010, the second year after the introduction 
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of the Pentavalent vaccine to the national immunization schedule. This is 
known as the Webber effect; a tendency to report any adverse event after the 
introduction of a new vaccine into the immunization schedule (Australian 
Government, 2008).  This period is followed by a constant level of reporting 
rates of adverse events after DTwP administration. 
 
Figure 1.  Reporting rates of adverse events after administration of DTwP containing 
vaccines from 2003 to 2015. 
 
Dose number  
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 2. Frequency of adverse events reported after administration of DTwP-containing 
vaccines versus dose number 
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 About 38,8%(107/275) of the reactions occurred after the first 
administered dose of DTP vaccine. However, 80.3% (86/107) of these 
reported adverse events after the first dose administration are just events of 
fever over 38 0C. 43,8% (28/64) of the local reactions also occurred after the 
first dose. Persistent crying occurred most frequently with the initial dose 
and less often thereafter (7/11). More severe reactions like convulsions 
occurred at the same frequency after the first and second dose (6/17 and 5/17 
cases respectively). Anaphylaxis occurred more frequently after the first dose 
administration (5/8). In 4 out of 6 cases the convulsions occurred after the 
first dose. According to WHO, children who experienced local reactions 
after pertussis vaccine have an enhanced probability of experiencing the 
same reaction with a following dose (Deloria et al., 1995). Two studies 
conclude that the frequency of local reactions tends to increase with the 
number of doses while systemic reactions, with the exception of fever, may 
diminish with subsequent doses (Cody, Baraff, Cherry, Marcy & Manclark, 
1981 ; Pollock, Miller, Mortimer, & Smith, 1984). This is not observed in 
our analysis. 
 
Uncommon serious reactions 
 Cody et al., reported that DTwP vaccine is associated with febrile 
seizures (0.06 % of the vaccinees) and the risk for seizures after DTwP 
administration is higher in children with personal or family histories of 
convulsions (Cody et al., 1981). However simple febrile convulsions in 
children are considered to be benign with no evidence for risk of epilepsy. 
There were no cases of Hypotonic-Hyporesponsive-Episode (HHE) reported 
after DTwP immunization in Albanian children. The Cody and colleagues 
study detected an incidence of HHE of 0.06 % after immunization of 
children with DTwP-vaccine (Cody et al.,1981). Serious reactions constitute 
30 % (84/275) of all cases reported after administration of DTwP-containing 
vaccines in Albania. The frequency of non-serious reaction is significantly 
higher than that of serious reactions (p=0.000, χ2 = 41,6). The definition of 
serious reaction is based on the definition made by WHO: Serious adverse 
events following immunization are considered those that result in death; are 
life-threatening; require in-patient hospitalization or prolongation of 
existing hospitalization; result in persistent or significant 
disability/incapacity, or; are a congenital anomaly/birth defect (WHO, 
2000). 96,8 % of the  non-serious cases healed after treatment compared with  
89,4 % of the serious  group. 48,8 % of the serious cases occurred during 
2004, which corresponds to the second year of implementation of AEFI 
reporting system. After this year the frequency of reporting of serious AEFI 
has been constant throughout the years. 
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AEFI severity Health condition after treatment 
Not healed Healed Total 
Non Serious 5 149 154 
  3,20% 96,80% 100,00% 
Serious 7 59 66 
  10,60% 89,40% 100,00% 
Total  12 208 220 
  5,50% 94,50% 100,00% 
Table 1. Outcome of treatment of serious and non-serious cases 
 
Anaphylaxis  
 Because of the controversy in defining the anaphylaxis and lacking of 
a widely accepted definition of this term, there is variability in the data 
reporting this type of adverse effect (Ruggeberg et al., 2007). It is not known 
whether the reported event as anaphylaxis is referred to the immediate 
hypersensitivity reaction (type I anaphylaxis) or to a life-threatening clinical 
event. Taking in consideration the levels of certainty of Brighton 
Collaboration case definition, which is conform with  the definition of 
European Academy of Allergy and Clinical Immunology (EAACI’s) and the 
American Academy of Pediatrics’, the definition of anaphylaxis in this study 
analyses the cardiovascular and/or respiratory involvement in presence of 
skin reactions and multisystem findings (Johansson et al., 2001). 
Anaphylaxis is a rare event in infancy and the background rates are not well-
known (Ruggeberg et al., 2007). The Committee to Review Adverse Effects 
of Vaccines in 2012 concluded that the evidence convincingly supports a 
causal relationship between tetanus toxoid  vaccine and anaphylaxis (IOM, 
1991). In this study the mean value of rate of anaphylaxis after DTwP 
administration to Albanian children is 0,45/100.000 doses of DTwP 
administered (p=0,023 CI: 0.06-0,73) and a normal distribution of rates 
throughout years. In the WHO vaccine rates information’s sheets of DTwP 
vaccine it is reported a rate of 0.13 (CI; 0.003 to 0.71) cases per 100,000 
administered doses ( Bohlke et al., 2003). Most of the cases occurred after 
the first dose administration (5/8) and data suggest that this might be related 
to the presence of IgG antibodies transmitted from the mother. Generalized 
urticaria was reported in 5 cases, 1 of which reported as anaphylaxis, while 
rash was reported in 9 cases, angioedema in 4 cases, cyanosis in 6 cases and 
erythema in 6 cases. However it should be specified that the occurrence of 
these symptoms without a definite cause is not rare in infancy and their 
frequency after DTwP immunization has already been reported (WHO, 
2014). 
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Encephalopathy, Encephalitis and Seizures 
 There have been ongoing discussions about relationship between 
DTwP containing vaccines and encephalopathy (Fenichel, 1982). Although 
the terms encephalopathy and encephalitis are used interchangeably to 
indicate a set of symptoms like alterations in behavior or level of 
consciousness, convulsions, headache and focal neurological deficits, the 
term encephalitis implies an inflammatory reaction within the brain. 
Conversely, the term encephalopathy does not and it is frequently 
accompanied by febrile or non-febrile seizures although the latter alone is 
not a diagnosis for the former (Sejvar et al., 2007). Convulsions are motor 
manifestations of seizures (Ray et.al., 2006). Due to the variability of clinical 
symptoms and signs of the disease, the difficulty to distinguish between the 
two brain pathologies and the absence of a precise definition, it is difficult to 
give a definitive answer regarding the reporting rates of neurological adverse 
effects after DTwP vaccination in Albanian children. Seizures are much 
more common in children than is encephalopathy and it is probable that the 
majority of cases reported as encephalopathy might be acute symptomatic 
seizures. Although the report of Institute of Medicine in 1994 concluded that 
“the balance of evidence is consistent with a causal relationship between 
DTwP and chronic nervous system dysfunction in children whose serious 
acute neurological illness occurred within 7 days of a DTwP vaccination”, 
recent studies do not confirm an association between DTwP and acute 
encephalopathy (Ray et.al., 2006). Moreover, increasing sophisticated 
diagnostic tools have revealed other causes, including Daveret syndrome, for 
almost all of the severe neurological syndromes that follow childhood 
vaccination and have been previously erroneously attributed to them (Ray 
et.al., 2006). 
 In our study, there has been in total 3 cases of encephalitis and the 
reporting rates has been 0,7 cases/100,000 of DTwP administered doses. In 
one case encephalitis was accompanied by convulsions and in another case 
with persistent crying and vomiting. Only one case was followed up at the 
moment of reporting but there is no follow up study. While the mean value 
of convulsions rate has been 0,95 cases/100,000 doses of DTwP vaccine 
administered (p=0.003, CI: 0,31-1,42) there has been in total 17 cases of 
convulsions, 10 of which accompanied by febrile convulsions and in  4 cases 
by cyanosis . Only 3 cases with convulsions were being followed up at the 
moment of reporting. The other cases had no neurological impairment. It 
should be noted that all of these rates for encephalopathy after DTwP 
vaccination are significantly less than the risk for encephalopathy after B. 
pertussis infection itself ( Rantala & Uhari, 1989). 
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Persistent crying 
 Various types of studies like case reports, case series and controlled 
epidemiological studies have concluded that persistent crying after DTwP 
vaccination is probably caused by pain, local reaction, and fever (Bonhoeffer 
et al., 2013). The Committee to review adverse effects of vaccines in 1991 
concluded that the evidence indicates a cause-effect relationship between the 
pertussis component of DTwP vaccine and protracted, inconsolable, or high-
pitched crying or screaming (IOM, 1991). The rate of persistent crying varies 
with type and dose of vaccine and immunization site.  Since in this study the 
duration of persistent crying is not reported and neither the crying continuity, 
it is difficult to meet the Brighton Collaboration case definition for persistent 
crying (Bonhoeffer et al., 2013). However the rate of reporting is 0,6 cases 
per 100,000 administered doses. There have been 11 cases of persistent 
crying reported. In 9 cases fever was also reported and in 1 case convulsions 
and cyanosis and the children were all recovered after receiving treatment. 
7/11 of the cases occurred after the first dose administration .This is 
consistent with the DTwP rates information sheets of WHO and Multicenter 
Acellular Pertussis Trial (WHO, 2014; Decker & Edwards , 1996). 
 
Common minor reactions 
 Other researchers reported that minor local reactions, as redness, 
swelling, and pain at the site of injection, occur in about half of DTwP 
recipients (Cody et al., 1981).  These reactions as well as minor systemic 
reactions such as fever, irritability, and drowsiness occur five times more 
frequently after DTwP than after DT vaccine administration (Cody et al., 
1981).  The frequency of common reactions after DTwP administration vary 
among the lots and manufacturers, while local reaction rates vary with the 
number of prior DTwP injections (Baraff, Cody & Cherry, 1984). 
 
Abscess 
 There are in total 6 cases of abscess reported, 4 of which have 
occurred after administration of the first dose. Three of them were 
accompanied by fever while in the other two edema and erythema was 
reported. None of these cases meets the first level of diagnostic certainty of 
Brighton Collaboration because laboratory confirmation was not developed 
(Kohl et al., 2007). Local reactions like redness and tenderness have been 
associated with infectious abscesses which are also accompanied by fever. 
The sterile abscesses (cold abscess) are typically not accompanied by fever 
or lymphadenopathy (Kohl et al., 2007). All the cases, but one, were 
recovered without sequelae after receiving an adequate treatment. 
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Local reactions 
 This is the second most common group of adverse events reported 
after the fever. Local reactions constitute 11,3 % of all adverse effects 
reported after DTwP vaccination. Limb pain was reported in 4 cases, local 
redness in 6 cases, local swelling in 9 cases and local pain in 1 case. 
Although there is no standardized definition, a “local reaction” is any 
description of morphological or physiological change at or near the injection 
site (Gidudu, 2008). The rate of local reactions depend on various factors 
like technique and methods of vaccine administration, manufacturing lot, 
storage conditions of the vaccine, genetic predisposition and route of 
administration. 24/31 of the cases resolved after ambulatory treatment while 
7/31 of the cases resolved after hospital treatment. 41,9 % of local reactions 
occurred after first dose and 22,6 % after booster dose. This is inconsistent 
with the Cody and colleagues study which concludes that local reactions 
increased in frequency with successive doses.  Local reactions are usually 
attributed to the B. pertussis-containing component (Cody et al., 1981).   
 
Rash 
 There are many morphologies of rash which describe mucocutaneous 
changes after vaccination. It is important to report the color, number, size, 
morphology and anatomic distribution of the observed skin lesions (Beigel 
et.al., 2007). Rash was reported in 9 cases, generalized urticaria in 5 cases, 
local urticaria in 4 cases and  cyanosis in 7 cases. 90,5 % of the cases 
recovered without any sequelae. Anyway the committee to review the 
adverse events of vaccines concluded that there is insufficient evidence to 
indicate a causal relation between DTwP vaccine or the B. pertussis 
component of DTwP vaccine and any kind of rash (IOM, 1991). 
 
Fever 
 Fever is defined as the endogenous elevation of at least one measured 
body temperature of  ≥38 ◦C and is distinguished from hyperthermia which 
is a body warming caused by external environmental factors (Bouchama & 
Knochel, 2002). Fever was the most frequently reported adverse event after 
DTwP administration. Although the accuracy of measurement and errors in 
measurement method are not specified and this might influence the reporting 
rates. Mean fever rate is 12 cases/100.000 doses administered. The fever 
rates does not differ significantly throughout years but there is a significant 
increase in 2004 (112/234 of the cases, p=0.046), the second year after 
implementation of AEFI reporting system. 80,3 % of the cases with fever 
were classified as non-serious while 25,9 % as serious reactions. Fever over 
40 ◦C was reported in 3 % of the cases (7/234). The number of healed cases 
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is higher than the number of non-healed cases ( p=0.000). The fever working 
group at Brighton Collaboration case definitions conclude that fever 
following administration of an inactivated component or live vaccine may be 
temporally associated with, but is not necessarily the result of the 
administration of a vaccine (Marcy et al., 2004). It should be recognized that 
background rates of fever are high. The value of  ≥38 ◦C is accepted as 
reflecting an abnormal elevation of temperature, irrespective of device, 
anatomic site, age, or environmental conditions (Marcy et al., 2004). In our 
study, the incidence of fever was approximately the same after the three 
doses of DTwP, while only 10,8 % of the cases with fever occurred  after a 
booster dose administration of DTwP vaccine. Our results about fever rates 
after DTwP administration are consistent with the results from Braun et al. 
who found that fever was the most commonly reported event for DTwP, 
occurring in  851 of 1939 infants (43.9 %) (Braun et al., 2000).  While the 
incidence of fever increases substantially after the first dose (37 % of the 
cases), this is in disagreement with the results of Multicenter Acellular 
Pertussis Trial in which the incidence and severity of fever increased 
substantially with successive doses of the reference whole-cell vaccine 
(Decker & Edwards, 1996). 
 
Discussion 
 In this study, the cases reported with encephalopathy, anaphylaxis 
and temperature over 40 ◦C were not investigated and there were not made 
search for other causes, therefore conclusions about their relationship with 
DTwP combined vaccines cannot be reached.  
 Studies have shown that the reactogenicity to wP containing vaccines 
is significantly reduced when given in early short time-frame schedules 
(Miller et al., 1997). The Albanian immunization schedule is well studied 
and designed according to World Health Organization recommendations 
which is reflected also in the rates of adverse events following DTwP 
vaccines. Rates of adverse events over the years did not changed 
significantly except the second year after the implementation of AEFI 
reporting system and the second year after the introduction of the 
Pentavalent vaccine formulation. Although it is difficult to evaluate and 
specifically attribute adverse events to a single vaccine after the 
administration of combined vaccines, the introduction in 2009 of the 
combined Pentavalent vaccine in Albania did not increase the rate and the 
nature of adverse events observed before 2009 when DTwP was 
administered alone to children. This is consistent with the Cochrane review 
in 2012 which found that the use of combined versus separate components of 
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the vaccine did not increase the incidence of serious adverse events RR.0,94. 
(CI: 0.58-1.53) (Bar-On et al., 2012). 
 Studies aimed at evaluate the relationship between the site of 
injection and the incidence of adverse reactions in DTwP recipients 
concluded that the administration of vaccine in the buttock elicited less local 
and systemic reactions than the injection in the thigh (Baraff et al., 1984). 
Administration of aluminum-absorbed vaccines into subcutaneous tissue 
instead of muscle has been associated with a higher rate of local reactions as 
aluminum hydroxide crystals may remain at the injection site possibly 
creating local inflammation and sterile abscess  (Bergeson, Singer & Kaplan, 
2004 ; Jefferson, Rudin & Di Pietrantonj, 2004). This analysis is limited 
because we do not have, for every recorded AEFI, the number of vaccine lot 
and the brand name of the manufacturer. Furthermore, the injection site is 
not known and the immunization method and technique of administration are 
also not available. 
 Because DTwP containing vaccines are administered to children at an 
age when disorders like encephalopathy, infantile spasms, neurological 
conditions, and SIDS are most likely to occur, it is possible that they occur 
after the administration of DTwP containing vaccines although the causes 
might be unrelated to the vaccine or vaccination. Studies have disseminated 
concerns about relationship between DTwP and such conditions (Howson & 
Fineberg, 1992). Although wP vaccine are gradually replaced by aP vaccine 
in the industrialized world, the health and economic impact should be 
evaluated before the introduction of a new vaccine and the shift in 
formulation should be driven by safety considerations. Recent mathematical 
modeling studies from Australia, England and Wales and USA indicate that 
interchanging from wP to aP may be associated with disease resurgence after 
a few years which might also increase the risk of deaths from B. pertussis 
infection (Tozzi et al., 1998). In the pertussis position paper, WHO advises 
that National Immunization Programs currently administering wP vaccines 
should continue to use wP vaccines for primary vaccination series (WHO, 
2016). Indeed, experiments performed in the baboon model, the aP vaccines 
protected against the disease but had limited impact on transmission of the 
agent to other animals, whereas DTwP vaccines are effective in preventing 
infection and transmission (Warfel & Merkel, 2014). Besides all, when used 
in combination with inactivated whole-cell B. pertussis vaccine, the humoral 
immune response to diphtheria and tetanus toxoid is ehanced because of the 
intrinsic adjuvant properties of whole-cell B. pertussis. 
 Recent data indicate that B. pertussis strains have evolved and 
changed the genomic sequence of virulence factors over time, with isolates 
differing in pre and post vaccination era (Korkmaz1, Aydin & Unal, 2014). 
An improved form of DTwP with reduced endotoxin content has been 
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produced for more than 30 years by the Instituto Butantan in Brazil, and 30 
million doses have been administrated to Brazilian children every year, with 
over 95 % coverage without severe adverse events reported (Dias et.al., 
2012). It may be interesting to evaluate the possible benefits of introducing a 
similar type of vaccine also in our country. During the last years, the 
reporting rate has reached a constant level which confirms that Albanian 
surveillance system of adverse events after children vaccination is well-
functioning. The health workers are aware of the importance of reporting any 
adverse event, and also the measures and legal provisions undertaken by the 
Ministry of Health through the Institute of Public Health are well functioning 
leading to the establishment of a AEFI Surveillance System in accordance 
with the World Health Organization directives. 
 
Conclusion 
 The overall rates of adverse events after administration of wP 
containing vaccines in Albanian children were within the range expected in 
WHO DTwP vaccine rates information sheet. Also the nature and pattern of 
reactions were not severe and the numbers of serious reactions were 
significantly low. Other severe events reported in DTwP rates information 
sheet like Hypotonic Hyporesponsive episode, Davret syndrome, aseptic 
meningitis, brachial neuritis, sudden infant death syndrome, Reyes 
syndrome, epilepsy, chronic neurological damage, hemolytic anemia, 
juvenile diabetes, peripheral mononeuropathy or thrombocytopenia were not 
reported. In this analysis most of the events occur after the first administered 
dose, and they start to fall after the second dose reaching a minimum level 
after the booster dose which is inconsistent with the reports from WHO 
(WHO, 2014).  This fact might reflect the underreporting trend and the trend 
not to report mild and common reactions which increase with increasing 
doses of the vaccine. Anyway underreporting is not at concerning levels 
since the rates of AEFI fall within the expected limits stabilized by WHO. 
Moreover, among children, lower diphtheria toxoid content generally results 
in a decreased reactogenicity of booster doses (WHO, 2000). 
 In our study several brands of Pentavalent vaccine were reported. but 
limited data suggest no interchangeability between different products of 
vaccines as the differences in adverse reaction rates may be due to 
differences in DTwP vaccine preparations, antigenic content, methods and 
lots of production (Baraff et al., 1984). 
 All these observations lead to the conclusion that the DTwP-
containing vaccines employed in Albania do not raise relevant concerns 
about safety. Nevertheless it should be emphasized that the small number of 
cohorts and the rarity of this events makes it difficult the occurrence and 
detection of this events in a small country like Albania. 
European Scientific Journal November 2016 edition vol.12, No.33  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
52 
References: 
1. Australian Government . (2008). Department of Health Additional 
reports – childhood immunisation coverage. Commun Dis Intell 32, 
288–9. Retrieved from 
http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-
cdi3304a.htm 
2. Baraff , L.J., Cody, C.L., & Cherry, J.D. (1984). DTP-associated 
reactions: an analysis by injection site, manufacturer, prior reactions, 
and dose. Pediatrics, 73, 31-36. Available from 
http://pediatrics.aappublications.org/content/73/1/31.long 
3. Bar-On ES, Goldberg, E., Hellmann, S., & Leibovici, L .(2012). 
Combined DTP-HBV-HIB vaccine versus separately administered 
DTP-HBV and HIB vaccines for primary prevention of diphtheria, 
tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). 
Retrieved from Cochrane Database  of Systematic Reviews, 
(4):CD005530. doi: 10.1002/14651858.CD005530.pub3.  
4. Beigel, J., Kohl, K.S., Khuri-Bulos, N., Bravo, L., Nell, P., Marcy, 
S.M., … Maurer, T. (2007). Rash including mucosal involvement: 
Case definition and guidelines for collection, analysis, and 
presentation of immunization safety data. Vaccine , 25, 5697–5706, 
doi:10.1016/j.vaccine.2007.02.066 
5. Bergeson, PS., Singer, SA., & Kaplan,  AM.(1982). Intramuscular 
injections in children. Pediatrics, 70(6), 944-8. Retrieved from 
http://pediatrics.aappublications.org/content/70/6/944.long?sso=1&ss
o_redirect_count=1&nfstatus=401&nftoken=00000000-0000-0000-
0000-
000000000000&nfstatusdescription=ERROR%3a+No+local+token 
6. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., 
Black S.B., Mullooly J.P., & Thompson R.S. (2003). Risk of 
anaphylaxis after vaccination of children and adolescents. Pediatrics, 
112(4), 815 -20.  
7. Bonhoeffer,  J., Imoukhuede,  E.B.,  Aldrovandi, G., Bachtiar,  NS., 
Chan,  ES., Chang,  … Heininger U.(2013). Template protocol for 
clinical trials investigating vaccines--focus on safety elements. 
Vaccine,  31(47), 5602-20. doi: 10.1016/j.vaccine.2013.02.041. 
8. Bouchama, A., & Knochel, JP. (2002). Heat stroke. N Engl J Med, 
346, 1978– 88.  
9. Braun, MM., Mootrey, GT., Salive, ME., Chen, RT., & Ellenberg, 
SS. (2000).  “Infant immunization with acellular pertussis vaccines in 
the United States: assessment of the first two years’ data from the 
Vaccine Adverse Event Reporting System (VAERS)”. Pediatrics, 
European Scientific Journal November 2016 edition vol.12, No.33  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
53 
106(4), E51. Retrieved from 
http://pediatrics.aappublications.org/content/106/4/e51.long 
10. Cody, C.L., Baraff,  L.J., Cherry, J.D., Marcy S.M., & Manclark C.R. 
(1981).  “Nature and rates of adverse reactions associated with DTP 
and DT immunizations in infants and children”. Pediatrics, 68, 650-
660 .Retrieved from 
http://pediatrics.aappublications.org/content/68/5/650.long 
11. Decker, M.M., Edwards, K.M., & Bogaerts, H.H. (2008). 
Combination Vaccines. In Plotkin, SA., Orenstein, WA. eds. 
Vaccines, 5th ed. Philadelphia, PA, WB Saunders Company, 139–
156. ISBN13: 978-1416036111 
12. Decker, MM., & Edwards, KM (1996). The multicenter acellular 
pertussis trial: An overview. Journal of Infectious Diseases, 174, supl 
3, S270–S275. Retrieved from 
http://jid.oxfordjournals.org/content/174/Supplement_3/S270.long 
13. Deloria, M.A., Blackwelder, W.C., Decker M.D., Englund J.A., 
Steinhoff M.C., Pichichero M.E. … Edwards K.M. (1995). 
Association of reactions after consecutive acellular or whole-cell 
pertussis vaccine immunizations. Pediatrics, 96(3 pt 2),  592-594. 
Retrieved from 
http://pediatrics.aappublications.org/content/96/3/592.long?sso=1&ss
o_redirect_count=1&nfstatus=401&nftoken=00000000-0000-0000-
0000-
000000000000&nfstatusdescription=ERROR%3a+No+local+token 
14. Dias, W.O., van der Ark, A.A.J,  Sakauchi, M.A.,  Kubrusly, F.S.,  
Prestes, A.F.R.O., Monamaris … Isaias R. (2013). An improved 
whole cell pertussis vaccine with reduced content of endotoxin.  
Human Vaccines & Immune-therapeutics 9(2), 339–348. 
doi:  10.4161/hv.22847 
15. Fenichel, GM. (1982). “Neurological complications of 
immunization”. Annals of Neurology, 12(2), 119-28. doi: 
10.1002/ana.410120202 
16. Gidudu , J.(2008). A local reaction at or near injection site: Case 
definition and guidelines for collection, analysis, and presentation of 
immunization safety data. Vaccine, 26,  6800–6813,  
doi:10.1016/j.vaccine.2008.10.006 
17. Gold, M., Kempe, A., & Osbourn, M. (1999).  “A comparison of 
serious adverse reactions to whole cell and acellular pertussis 
vaccines in South Australia”.  Med J Aust, 171(6), 331–Available 
from 
https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%9CA+comp
arison+of+serious+adverse+reactions+to+whole+cell+and+acellular+
European Scientific Journal November 2016 edition vol.12, No.33  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
54 
pertussis+vaccines+in+South+Australia%E2%80%9D.++Med+J+Au
st 
18. Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi , AE., 
… Anemona, A. (1996). A controlled trial of two acellular vaccines 
and one whole-cell vaccine against pertussis. Progetto Pertosse 
Working Group. N Engl J Med , 334(6), 341-8. doi: 
10.1056/NEJM199602083340601, Retrieved from 
http://www.nejm.org/doi/full/10.1056/NEJM199602083340601 
19. Howson, C.P., Fineberg, H.V. (1992). Adverse events following 
pertussis and rubella vaccines: summary of a report of the Institute of 
Medicine. JAMA, 267(3), 392-396. 
doi:10.1001/jama.1992.03480030070039.  
20. Institute of Medicine (U.S.). Committee to Review the Adverse 
Consequences of Pertussis and Rubella Vaccines (1991). Adverse 
Effects of Pertussis and Rubella Vaccines: A Report of the Committee 
to Review the Adverse Consequences of Pertussis and Rubella 
Vaccines. Washington, D.C. : National Academy Press, 1991 . ISBN: 
0309044995 
21. Institute of Medicine. (1991). “Adverse effects of vaccines: Evidence 
bearing on causality”. The National Academies Press, Washington, 
DC. Available from  https://www.nap.edu 
22. Jefferson, T., Rudin, M., & Di Pietrantonj, C.(2004). Adverse events 
after immunisation with aluminium-containing DTP vaccines: 
systematic review of the evidence. Lancet Infect Dis, 4, 84-90. 
http://dx.doi.org/10.1016/S1473-3099(04)00927-2 
23. Johansson, SG., Hourihane, JO., Bousquet, J., Bruijnzeel-Koomen, 
C., Dreborg, S., … Haahtela, T.(2001). A revised nomenclature for 
allergy. An EAACI position statement from the EAACI 
nomenclature task force. Allergy, 56(9), 813–24. doi: 10.1111/j.1398-
9995.2001.00002.x-i1  
24. Kohl, K.S., Ball, L., Gidudu, J., Hammer, S.J., Halperin, S., Heath, 
P., … Walop, W. (2007). Abscess at injection site: Case definition 
and guidelines for collection, analysis, and presentation of 
immunization safety data. The Brighton Collaboration Local 
Reactions Working Group for Abscess at Injection Site.  Vaccine , 
25, 5821–5838. doi: 10.1016/j.vaccine.2007.04.057 
25. Korkmaz1, H.A., Aydin, A., & Unal, B.(2014). Comparison of 
acellular pertussis-tetanusdiphtheria vaccines and whole-cell 
pertussistetanus- diphtheria vaccines in infancy. Paediatr Int Child 
Health, 34(3), 198-202. doi: 10.1179/2046905513Y.0000000110. 
26. Marcy, S.M.,Kohl K.S.,  Dagan, R.,  Nalin, D., Blum, M., Jones, 
M.C., … Vermeer, P. (2004). Fever as an adverse event following 
European Scientific Journal November 2016 edition vol.12, No.33  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
55 
immunization: case definition and guidelines of data collection, 
analysis, and presentation. Vaccine, 22: 551–556,  
doi:10.1016/j.vaccine.2003.09.007 
27. Miller E., Ashworth L.A., Redhead K., Thornton C., Waight P.A., 
&Coleman T. (1997). “Effect of schedule on reactogenicity and 
antibody persistence of acellular and whole-cell pertussis vaccines: 
value of laboratory tests as predictors of clinical performance”. 
Vaccine, 15, 51-60.Retrieved from  
http://www.sciencedirect.com/science/article/pii/S0264410X9600112
0 
28. Mortimer, E. Pertussis. In: Plotkin, S., Mortimer, E., et al.,. Vaccines. 
2nd ed. Philadelphia, PA: WB Saunders; 1994. 
29. Pollock, TM., Miller, E., Mortimer, JY., & Smith, G. (1984). 
“Symptoms after primary immunization with DTP and DT vaccine”.  
Lancet, 2, 146-149. http://dx.doi.org/10.1016/S0140-6736(84)91057-
2 
30. Rantala, H., & Uhari, M.(1989). Occurrence of childhood 
encephalitis: A population- based study.  Pediatric Infect Dis J8, 
426–430.Available from https://science.report/pub/16604795 
31. Ray, P., Hayward, J.,  Michelson, D., David M.D., Lewis, E., 
Schwualbe, J., … Robert M.D. (2006).  Encephalopathy after Whole-
Cell Pertussis or Measles Vaccination Lack of Evidence for a Causal 
Association in a Retrospective Case–Control Study. The Pediatric 
Infectious Disease Journal,  25(9), 768-73. doi: 
10.1097/01.inf.0000234067.84848.e1 
32. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer. J., 
Friedlander.S., … Simpson N.(2007). “Anaphylaxis: Case deﬁnition 
and guidelines for data collection, analysis, and presentation of 
immunization safety dat”. Vaccine, 25(31),  5675-84. 
doi:10.1016/j.vaccine.2007.02.064  
33. Sejvar, J. J., Kohl, K. S., Bilynsky, R., Blumberg, D., Cvetkovich, T., 
Galama, J., ... null, null (2007). Encephalitis, myelitis, and acute 
disseminated encephalomyelitis (ADEM): Case definitions and 
guidelines for collection, analysis, and presentation of immunization 
safety data. Vaccine, 25(31), 5771-5792. DOI: 
10.1016/j.vaccine.2007.04.060 
34. Tozzi A.E., CiofidegliAtti, M.L., FiteWassilakj, S.G., Salmaso, S., 
Panei, P., Anemona,  A., Luzi, S., & Greco, D. (1998). Predictors of 
adverse events after the administration of acellular and whole cell 
diphtheria-tetanus-pertussis vaccines.  Vaccine, Vol. 16, 320-
322,.Available from 
https://www.ncbi.nlm.nih.gov/pubmed/?term=Predictors+of+adverse
European Scientific Journal November 2016 edition vol.12, No.33  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
56 
+events+after+the+administration+of+acellular+and+whole+cell+dip
htheria-tetanus-pertussis+vaccines. 
35. Warfel, J.M., & Merkel, T.J. (2014). Reply to Domenech de Celles et 
al.: Infection and transmission of pertussis in the baboon model.  
Proc Natl Accad Ssci USA, 111(7), E718 doi: 
10.1073/pnas.1324074111 
36. World Health Organisation. (2016, March 14). Pertussis vaccines: 
WHO position paper, August 2015—Recommendations Vaccine, 
34(12),1423–1425. http://dx.doi.org/10.1016/j.vaccine.2015.10.136 
37. World Health Organization .(2014). Information Sheet, Observed rate 
of vaccine reactions – Diphtheria, pertussis, tetanus vaccines. 
Retrieved from  
http://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/
. Last seen on August 2016. 
38. World Health Organization. Dept. of Vaccines and Biologicals. 
(2000).  “Supplementary information on vaccine safety, Part 2: 
Background rates of adverse events following immunization”.  
Geneva : World Health Organization. Retrieved from 
http://www.who.int/iris/handle/10665/66675 
 
  
